2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3782 Pegylated interferon discontinuation for myeloproliferative neoplasm: A single center, prospective, observational study

Long Chang, MD, Hao Cai2, Jian Li, MD3, Minghui Duan, MD4
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background

Polycythemia vera (PV) and essential thrombocythemia (ET) are classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). Long-acting interferons (Pegylated interferon or Ropeginterferon) have emerged as the preferred option for cytoreductive therapy in MPNs, for achieving sustained hematological remission and molecular remission. However, it was uncertain that whether interferon can be discontinued and how to implement this discontinuation while maintaining sustained remission. The aim of this study is to evaluate the safety and feasibility of discontinuing Pegylated interferon (Peg-IFN-a-2b) therapy after achieving sustained complete remission—as assessed by hematological, molecular, and bone marrow pathological criteria—in patients with myeloproliferative neoplasms.

Methods

Patients were considered eligible for this study if they met the following criteria: (i) diagnosis of PV or ET in accordance with the World Health Organization 2022 classification criteria (ii) ages 18 years or older (iii) detectable driver gene mutation (JAK2, CALR, or MPL) at disease onset; (iv) complete remission at least twice, with intervals of more than 12 months. Complete remission is defined as the simultaneous fulfillment of the following criteria: complete hematologic remission, complete molecular remission, and normal bone marrow biopsy findings. Molecular response (MR) was assessed using the IWG-MRT ELN 2009 criteria. Complete molecular remission (CMR) was defined as a reduction to <1% VAF. Disease progression to myelofibrosis, accelerated phase, or acute leukemia prior to discontinuation of treatment was excluded.

 

Patients were initially screened using a next-generation sequencing (NGS) panel for myeloid malignancies. After the presence driver mutation were confirmed, subsequent allele burden monitoring was performed exclusively by digital PCR (dPCR). Patients underwent dPCR monitoring twice annually.

Results

From January 2018 to December 2024, our hospital managed a cumulative total of 230 patients with PV and 124 patients with ET, all of whom underwent Peg-IFN-a-2b dose de-escalation strategy and were consistently monitored for driver mutations for a minimum duration of 24 months. Among them, 45 PV (19.5%, JAK2 V617F) and 15 ET (12.1%, 14 JAK2V617F, 1 CALR type 1 mutation) achieved CMR. Of them, 39 patients had complete remission as confirmed by bone marrow biopsy.

 

Ten patients with PV and 6 patients with ET fulfilled the criteria and discontinued Peg-IFN-a-2b. The median age was 51 (31-64), with males constituting 63%. After a median follow up of 12 months (6-18), no patient experienced disease progression or mortality. Every patient maintained sustained hematological and molecular remission at the last follow-up.

 

Conclusion

Patients receiving Peg-IFN-a-2b therapy for myeloproliferative neoplasms may be eligible to consider discontinuing treatment if they achieve sustained molecular complete remission and pathological complete remission.

Long Chang, MD: No relevant conflicts of interest to declare.